The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 78-90

  Hay, C R M ^a   Baglin, T P ^a   Collins, P W ^a   Hill, F G H ^a   Keeling, D M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Diagnosis; Factor VIII IX inhibitors; Management

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; CYCLOSPORIN A; PREDNISOLONE; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANAPHYLAXIS; BLEEDING; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; FACTOR IX; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; IMMUNE TOLERANCE; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS;

EID: 0033768130     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02327.x     Document Type: Review

References (96)

1. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
2. Von Willebrand factor contaminating porcine FVIII concentrate (Hyate: C) causes platelet aggregation
3. Recombinant factor VIIa in joint and muscle bleeding episodes
4. Immune tolerance and the immune modulation protocol
5. Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors
6. Induced immuneotolerance in factor VIII inhibitor patients
7. The use of porcine factor VIII:C in the treatment of patients with inhibitor antibodies to VIII:C: A multicenter US trial
8. Platelet activation induced by porcine factor VIII (Hyate: C)
9. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor
10. Inhibitor to factor VIII in a non-haemophilic patient: Evaluation of the response to DDAVP and the in vitro kinetics of factor VIII
11. FIX inhibitor, anaphylaxis and central nervous system haemorrhages in haemophilia B
12. The Use of recombinant factor VIIa (Novoseven) for central catheter insertion: An international experience
13. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-97): Current practice implications
14. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictors
15. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
16. Nephrotic syndrome as a complication of immune tolerance in hemophilia B
17. In vitro detection of mild inhibitors to factor VIII in haemophilia
18. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia
19. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies
20. Human factor IX inhibitors: Immunochemical characteristics and treatment with activated concentrate
21. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada
22. An acquired factor VIII inhibitor responsive to high-dose gamma globulin
23. A survey of 214 non-hemophilic patients with inhibitors to factor VIII
24. A prospective randomised trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies
25. Continuous infusion of monoclonal antibody-purified factor VIII: Rational approach to serious haemorrhage in patients with allo/autoantibodies to factor VIII
26. Pharmaco-economic aspects of inhibitor treatment
27. Use of recombinant FVIIa (Novoseven) in a patient with haemophilia B and anti FIX inhibitor
28. A patient with a spontaneous factor VIII:C autoantibody: Successful treatment with cyclosporin
29. Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors Organisation Inhibitor Working Party
30. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: The results of an international survey
31. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa
32. Dosing and monitoring of Novoseven treatment
33. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
34. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa
35. Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation
36. A more uniform measurement of factor VIII inhibitors
37. Prevalence of factor IX inhibitors among patients with haemophilia B. Results of a large-scale North American study
38. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of haemophiliacs with antibodies to factor VIII
39. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (novoseven in haemophiliacs with inhibitors
40. Calculations of factor VIII in vivo recovery and half-life
41. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up
42. Successful immunetolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate
43. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPACK study)
44. Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M
45. A two-phase linear regression model for biologic half-life data
46. The German National Immune Tolerance Registry, 1997 update
47. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor
48. Detection of factor VIII inhibitors with partial thromboplastin time
49. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy
50. Use of porcine factor VIII for surgical procedures in haemophilia A patients with inhibitors
51. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors benefits and limitations
52. Recombinant factor VIIa (Novoseven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors
53. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial
54. Autoplex versus proplex. A controlled, double-blind study of effectiveness in acute haemarthroses in hemophiliacs with inhibitors to factor VIII
55. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
56. Clinical experience with recombinant factor VIIa
57. A randomised, double blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors
58. Immune tolerance in hemophilia principal results from the international registry
59. Circulating anti-coagulants. A study of 40 cases and review of the literature
60. Low-dose immune tolerance induction in haemophilia A patients with inhibitors
61. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors: Experience in the Netherlands and Belgium
62. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor
63. Use of porcine factor VIII in the treatment of patients with acquired hemophilia
64. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/IX Standardisation Sub-Committee of the International Society for Thrombosis and Haemostasis
65. DDAVP, in acquired haemophilia A: Case report and review of the literature
66. Multicenter retrospective study on the utilisation of Feiba in France in patients with factor VIII and factor IX inhibitors
67. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII
68. Comparative study of four different pharmacokinetic computer programs: Case study of a factor VIII preparation
69. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate-purity pasteurised factor VIII concentrate
70. Cyclosporin treatment of a woman with acquired hemophilia due to factor VIII inhibitor
71. Novoseven (recombinant factor VIIa) in central nervous system bleeds
72. Successful immune tolerance treatment with monoclonal and recombinant factor VIII
73. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands
74. Factor VIII inhibitors on a SD-treated and pasteurised concentrate associated with specific batches and batch characteristics
75. Continuous infusion of porcine factor VIII in patients with acquired haemophilia
76. Home treatment with recombinant activated factor Vii in patients with factor VIII inhibitors: The advantages of early treament
77. Feasibility of using recombinant factor VIIa in continuous infusion
78. Cyclosporin therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus
79. A prospective study of the treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin
80. Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery
81. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. A double-blind clinical trial
82. Immune tolerance therapy for haemophilia A patients with acquired factor VIII antibodies: Comprehensive analysis of experience at a single institution
83. Acquired haemophilia and rheumatoid arthritis
84. Recombinant factor VIIa effective for repetitive central nervous system hemorrhage in an hemophilia B patient with high titre inhibitor
85. Corticosteroid therapy for acquired F VIIIC inhibitors
86. Acquired haemophilia and rheumatoid arthritis: Success of immunoglobulin therapy
87. Anti-idiotype suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous immunoglobulin
88. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders
89. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability
90. Management of haemophilia B patients with inhibitors and anaphylaxis
91. Nephrotic syndrome in hemophilia B patients with inhibitors
92. Home treatment with FEIBA for a patient with haemophilia B and factor IX inhibitors